Sponsor:
Johns Hopkins University
Code:
NCT07768267
Conditions
Irritable Bowel Syndrome (IBS)
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biocidin REMOVE
Placebo
Brief summary:
Conditions
Irritable Bowel Syndrome (IBS)
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Study ID
NCT07768267
Start date
Oct 26, 2026
Status verified date
Nov, 2026
Completion date
Dec 31, 2027
Anticipated
Primary completion date
Dec 31, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
40 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Biocidin REMOVE
placebo comparator: Placebo
Interventions
Biocidin REMOVE
Placebo
Primary outcome measure
Central contacts
Locations
Johns Hopkins Hospital
Recruiting
Baltimore, Maryland, United States, 21287
Principal Investigator:
Gerard Mullin, MD
Sponsor
Johns Hopkins University
Last update posted
Nov 16, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Johns Hopkins University on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.